Hologic, Inc.’s (HOLX) robust strength in the Molecular Diagnostics business is poised to drive growth in the upcoming quarters. Solid demand for breast imaging solutions aids the Breast Health division’s growth, with the company’s new buyout further diversifying the business. On top of that, broad-based performance in the international markets is highly promising for the stock. Meanwhile, the uncertain macroeconomic volatilities as well as adverse currency fluctuations can dent Hologic’s operations.In the ...